ArticleEmerging infectious diseases2019
Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections.
Article in Emerging infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.Nature communications · 2020Pooled it
- Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays.Reproductive biomedicine online · 2020Pooled it
- Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection.Scientific reports · 2022Trial
- COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain.The Journal of clinical investigation · 2020Trial
- Low Prevalence of Middle East Respiratory Syndrome Coronavirus Infection in Camel-Exposed Patients Presenting with Respiratory Symptoms in Northern Kenya.The American journal of tropical medicine and hygiene · 2025Article
- MERS-CoV seroconversion amongst Malaysian Hajj pilgrims returning from the Middle East, 2016-2018: results from the MERCURIAL multiyear prospective cohort study.Emerging microbes & infections · 2023Article
- Article
- Article
- Article
- Eleven-month SARS-CoV-2 binding antibody decay, and associated factors, among mRNA vaccinees: implications for booster vaccination.Access microbiology · 2023Article
- Time Course Evaluation of Enzyme-Linked Immunosorbent Assays Based on Cell-Free Recombinant Proteins for Detection of Antibodies against Middle East Respiratory Syndrome Coronavirus.Microbiology spectrum · 2022Article
- COVID-19: imbalanced cell-mediated immune response drives to immunopathology.Emerging microbes & infections · 2022Review
- Observations and Perspectives on Adaptive Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome.Nature communications · 2022Article
- An Insight Into Detection Pathways/Biosensors of Highly Infectious Coronaviruses.Molecular biotechnology · 2022Review
- Antibody Dynamics and Durability in Coronavirus Disease-19.Clinics in laboratory medicine · 2022Review
- Immunity to SARS-CoV-2 induced by infection or vaccination.Journal of internal medicine · 2022Review
- Recent advances in immunoassay technologies for the detection of human coronavirus infections.Frontiers in cellular and infection microbiology · 2022Review
- Two-years antibody responses following SARS-CoV-2 infection in humans: A study protocol.PloS one · 2022Article
- A magneto-optical biochip for rapid assay based on the Cotton-Mouton effect of γ-FeJournal of nanobiotechnology · 2021Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) infections in humans can cause asymptomatic to fatal lower respiratory lung disease. Despite posing a probable risk for virus transmission, asymptomatic to mild infections can go unnoticed; a lack of seroconversion among some PCR-confirmed cases has been reported. We found that a MERS-CoV spike S1 protein-based ELISA, routinely used in surveillance studies, showed low sensitivity in detecting infections among PCR-confirmed patients with mild clinical symptoms and cross-reactivity of human coronavirus OC43-positive serum samples. Using in-house S1 ELISA and protein microarray, we demonstrate that most PCR-confirmed MERS-CoV case-patients with mild infections seroconverted; nonetheless, some of these samples did not have detectable levels of virus-neutralizing antibodies. The use of a sensitive and specific serologic S1-based assay can be instrumental in the accurate estimation of MERS-CoV prevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.